Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
ChrysCapital invests $100 million in India’s Lenskart

From TechCrunch

By Manish Singh

June 15, 2023

ChrysCapital invests $100 million in India’s Lenskart

ChrysCapital has invested $100 million in Lenskart, the two said Thursday, pushing the Asian eyewear startup’s raise in the past year to $850 million as it expands its offerings and reach in international markets.

The Indian venture firm is buying shares worth $100 million in Lenskart through both primary and secondary transactions, the two said. The new investment follows Abu Dhabi Investment Authority announcing plans to invest $500 million in Lenskart. That investment, like the capital infusion from ChrysCapital, is an extension to last year’s round that valued the Indian startup at about $4.5 billion valuation.

“ChrysCapital is one of the most esteemed Indian equity partners, and it is my privilege to have them by our side. Incidences of myopia are rapidly growing globally, especially in Asia, including India, with big unsolved problems of access, affordability, and awareness. We believe that with the help of technology, customer centricity, and big investments in supply chain and talent, we can eradicate the problem of vision correction,” said Peyush Bansal, founder and chief executive of Lenskart, in a statement.

The 12-year-old Indian eyewear startup, which counts SoftBank and Alpha Wave Global among its backers, sells eyeglasses, sunglasses, contact lenses and other eyewear accessories. It has become one of the largest eyewear players in India by undercutting the competition, offering premium glasses at affordable prices.

Lenskart has been able to keep the prices low because it’s bringing more efficiency into the eyewear sector, Bansal told TechCrunch in a recent interview. The firm has built the expertise to manufacture its own eyeglasses and contact lenses and for many technologies, it’s the exclusive licensing partner for global firms in India, he said.

The startup, which currently has operations in India, Southeast Asia and the Middle East, sells its eye products online and through over 2,000 stores, three-fourths of which are in India. The startup is opening more than seven stores a week and plans to manufacture 20 million pairs of glasses next year.

Hundreds of millions of Indians need vision correction, but only a fraction of this population is currently wearing glasses or contact lenses. Bansal said the company will continue to scale its operations in India and existing international markets where it has operations because they remain highly underserved.

But what has helped Lenskart, and the eyewear industry at large, is just how quickly Indians are adopting glasses, he said. People are buying as many as four pairs of glasses every two years, a figure that is closely growing to five, he said, pointing to a similar popularity in sneaker purchases.

The startup is also slowly expanding its premium offerings, thanks to the acquisition of Japanese eyewear brand OwnDays and its new in-house brands such as John Jacobs.

“ChrysCapital is excited to back a strong execution-focused management team that has established dominant market leadership in the eyewear segment. Lenskart has been instrumental in developing this market, driven by its unwavering commitment to exceptional customer satisfaction, affordability, and reliability. With the acquisition of Owndays, there is an opportunity for Lenskart to expand across 10+ Asian countries in addition to the already large Indian market,” said Rajiv Batra, SVP at ChrysCapital, in a statement.

ChrysCapital invests $100 million in India’s Lenskart by Manish Singh originally published on TechCrunch

Most Recent

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

The de-extinction startup is looking to double or triple its previous valuation, according to the report.

Jul 20, 2026

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

The one-year-old startup aims to reinvent financial architecture for autonomous AI transactions.

Jul 20, 2026

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

AI infrastructure company Infinity announced Monday a $15 million raise at a $100 million valuation from investors including Touring Capital, Principal VC, and researchers from companies such as OpenAI and Anthropic.

Jul 20, 2026

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

For the first time since 2024, StrictlyVC is coming back to New York City — and we're bringing the kind of access you’d expect from an under-wraps event to the whole startup, VC, and dealmaking community.

Jul 20, 2026

Similar Posts

ADIA invests $500 million in Lenskart

ADIA invests $500 million in Lenskart

Lenskart has signed a definitive agreement to raise $500 million from the Abu Dhabi Investment Authority, they said Wednesday, at the height of the market slump as the Indian eyewear retailer bulks up its offerings and scales to international markets. The investment, an extension to last year’s round, helps the startup retain its $4.5 billion […]

Mar 15, 2023

Lenskart recovers from tepid open to close first day slightly above IPO price

Lenskart recovers from tepid open to close first day slightly above IPO price

Lenskart's public listing stirred debate over the nearly $8 billion valuation set in its IPO.

Nov 10, 2025

Accel could raise billions for India, but it’s sticking to $650 million

Accel could raise billions for India, but it’s sticking to $650 million

Accel has maintained its India fund size at $650 million for its eighth vehicle, even as other venture firms in the region are racing to raise increasingly larger pools of capital. The firm had ample opportunity to raise “multi-billion dollars,” said Shekhar Kirani, partner at Accel, in an interview with TechCrunch. But unlike peers who have supersized their funds, Accel is holding steady based on a calculated analysis of India’s venture opportunity. Peak XV has amassed $2.5 billion in its newe

Jan 5, 2025

India’s HealthKart valued at $500M in new investment

India’s HealthKart valued at $500M in new investment

Indian nutrition startup HealthKart’s valuation has surged to about $500 million in a new all-secondary investment of $153 million, two sources familiar with the matter told TechCrunch. The investment, one of the largest for an Indian consumer startup this year, was co-led by private equity firms ChrysCapital and Motilal Oswal, with Avendus Capital serving as financial advisor. A91 Partners and asset manager Neo Group also participated in the round. The startup was previously valued at $350 mil

Nov 18, 2024

Most Recent

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

The de-extinction startup is looking to double or triple its previous valuation, according to the report.

Jul 20, 2026

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

The one-year-old startup aims to reinvent financial architecture for autonomous AI transactions.

Jul 20, 2026

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

AI infrastructure company Infinity announced Monday a $15 million raise at a $100 million valuation from investors including Touring Capital, Principal VC, and researchers from companies such as OpenAI and Anthropic.

Jul 20, 2026

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

For the first time since 2024, StrictlyVC is coming back to New York City — and we're bringing the kind of access you’d expect from an under-wraps event to the whole startup, VC, and dealmaking community.

Jul 20, 2026

Similar Posts

ADIA invests $500 million in Lenskart

ADIA invests $500 million in Lenskart

Lenskart has signed a definitive agreement to raise $500 million from the Abu Dhabi Investment Authority, they said Wednesday, at the height of the market slump as the Indian eyewear retailer bulks up its offerings and scales to international markets. The investment, an extension to last year’s round, helps the startup retain its $4.5 billion […]

Mar 15, 2023

Lenskart recovers from tepid open to close first day slightly above IPO price

Lenskart recovers from tepid open to close first day slightly above IPO price

Lenskart's public listing stirred debate over the nearly $8 billion valuation set in its IPO.

Nov 10, 2025

Accel could raise billions for India, but it’s sticking to $650 million

Accel could raise billions for India, but it’s sticking to $650 million

Accel has maintained its India fund size at $650 million for its eighth vehicle, even as other venture firms in the region are racing to raise increasingly larger pools of capital. The firm had ample opportunity to raise “multi-billion dollars,” said Shekhar Kirani, partner at Accel, in an interview with TechCrunch. But unlike peers who have supersized their funds, Accel is holding steady based on a calculated analysis of India’s venture opportunity. Peak XV has amassed $2.5 billion in its newe

Jan 5, 2025

India’s HealthKart valued at $500M in new investment

India’s HealthKart valued at $500M in new investment

Indian nutrition startup HealthKart’s valuation has surged to about $500 million in a new all-secondary investment of $153 million, two sources familiar with the matter told TechCrunch. The investment, one of the largest for an Indian consumer startup this year, was co-led by private equity firms ChrysCapital and Motilal Oswal, with Avendus Capital serving as financial advisor. A91 Partners and asset manager Neo Group also participated in the round. The startup was previously valued at $350 mil

Nov 18, 2024